Evidence map›Paper›PMID 39616467›Full record

ArticleCancer2025

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

Alan H Bryce, Neeraj Agarwal, Himisha Beltran, Maha H Hussain, Oliver Sartor, Neal Shore, Emmanuel S Antonarakis, Andrew J Armstrong, Jeremie Calais, Michael A Carducci and 24 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Alan H BryceDepartment of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, Arizona, USA.ORCID https://orcid.org/0000-0002-0206-3895
Neeraj AgarwalHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Himisha BeltranDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Maha H HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA.
Oliver SartorDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Neal ShoreCarolina Urologic Research Center, Myrtle Beach, South Carolina, USA.
Emmanuel S AntonarakisMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
Andrew J ArmstrongDuke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0001-7012-1754
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, USA.
Michael A CarducciHopkins Kimmel Cancer Center, Baltimore, Maryland, USA.
Tanya Barauskas DorffCity of Hope Comprehensive Cancer Center, Duarte, California, USA.ORCID https://orcid.org/0000-0001-5990-298X
Jason A EfstathiouDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Martin GleaveUrological Sciences, Vancouver Prostate Center, University of British Columbia, Vancouver, British Columbia, Canada.
Leonard G GomellaDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Celestia HiganoMadrona Oncology, Seattle, Washington, USA.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
Andrei IagaruDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California, USA.
Alicia K MorgansDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
David S MorrisUrology Associates PC, Nashville, Tennessee, USA.
Michael J MorrisGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID https://orcid.org/0000-0002-9454-0096
Daniel P PetrylakYale New Haven Health, New Haven, Connecticut, USA.
Robert E ReiterJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA.
Matthew B RettigDivision of Hematology-Oncology, Department of Medicine, VA Greater Los Angeles, Los Angeles, California, USA.
Charles J RyanDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Scott B SellingerAdvanced Urology Institute, Tallahassee, Florida, USA.
Daniel E SprattUniversity Hospitals Seidman Cancer Center, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-5973-4741
Sandy SrinivasDivision of Medical Oncology, Stanford University Medical Center, Stanford, California, USA.
Scott T TagawaDivision of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0003-2777-8587
Mary-Ellen TaplinDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Evan Y YuDivision of Hematology and Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Tian ZhangDivision of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0001-8914-3531
Rana R McKayDepartment of Urology, University of California San Diego, La Jolla, California, USA.
Phillip J KooBanner MD Anderson Cancer Center, Phoenix, Arizona, USA.
E David CrawfordDepartment of Urology, University of California San Diego, La Jolla, California, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
Molecular mechanisms underlying lineage plasticity in prostate cancerR37CA241486 · NCI · DANA-FARBER CANCER INST · PI Himisha Beltran · 2020 to 2026
$4.1M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA077598NCI NIH HHS R37 CA241486NCI NIH HHS T32 CA009172
6 · The paper itself

Abstract

Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.

Indexed as

Neoplasm Recurrence, LocalProstatic NeoplasmsEvidence-Based MedicineHumansMalePoly(ADP-ribose) Polymerase InhibitorsPractice Guidelines as TopicProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantUnited StatesPoly(ADP-ribose) Polymerase InhibitorsProstate-Specific Antigenadvanced prostate cancerandrogen receptor pathway inhibitorsbiochemical recurrenceconsensus recommendationspoly(ADP‐ribose) polymerase (PARP) inhibitorsradioligand therapy

Identifiers

PMID39616467
PMCPMC11694557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.